| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS30022213 | HIV | ENSG00000198793.14 | protein_coding | MTOR | Yes | No | 2475 | P42345 |
| TVIS30022214 | HIV | ENSG00000198793.14 | protein_coding | MTOR | Yes | No | 2475 | P42345 |
| TVIS30022215 | HIV | ENSG00000198793.14 | protein_coding | MTOR | Yes | No | 2475 | P42345 |
| TVIS30022216 | HIV | ENSG00000198793.14 | protein_coding | MTOR | Yes | No | 2475 | P42345 |
| TVIS30022217 | HIV | ENSG00000198793.14 | protein_coding | MTOR | Yes | No | 2475 | P42345 |
| TVIS30022218 | HIV | ENSG00000198793.14 | protein_coding | MTOR | Yes | No | 2475 | P42345 |
| TVIS30022219 | HIV | ENSG00000198793.14 | protein_coding | MTOR | Yes | No | 2475 | P42345 |
| TVIS30022220 | HIV | ENSG00000198793.14 | protein_coding | MTOR | Yes | No | 2475 | P42345 |
| TVIS30022221 | HIV | ENSG00000198793.14 | protein_coding | MTOR | Yes | No | 2475 | P42345 |
| TVIS30022222 | HIV | ENSG00000198793.14 | protein_coding | MTOR | Yes | No | 2475 | P42345 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | MTOR |
|---|---|
| DrugBank ID | DB06233 |
| Drug Name | Ridaforolimus |
| Target ID | BE0002386 |
| UniProt ID | P42345 |
| Regulation Type | inhibitor |
| PubMed IDs | 23841999; 26199039; 25290091 |
| Citations | Bachegowda L, Gligich O, Mantzaris I, Schinke C, Wyville D, Carrillo T, Braunschweig I, Steidl U, Verma A: Signal transduction inhibitors in treatment of myelodysplastic syndromes. J Hematol Oncol. 2013 Jul 10;6:50. doi: 10.1186/1756-8722-6-50.@@Piha-Paul SA, Munster PN, Hollebecque A, Argiles G, Dajani O, Cheng JD, Wang R, Swift A, Tosolini A, Gupta S: Results of a phase 1 trial combining ridaforolimus and MK-0752 in patients with advanced solid tumours. Eur J Cancer. 2015 Sep;51(14):1865-73. doi: 10.1016/j.ejca.2015.06.115. Epub 2015 Jul 18.@@Brana I, Berger R, Golan T, Haluska P, Edenfield J, Fiorica J, Stephenson J, Martin LP, Westin S, Hanjani P, Jones MB, Almhanna K, Wenham RM, Sullivan DM, Dalton WS, Gunchenko A, Cheng JD, Siu LL, Gray JE: A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours. Br J Cancer. 2014 Nov 11;111(10):1932-44. doi: 10.1038/bjc.2014.497. Epub 2014 Oct 7. |
| Groups | Investigational |
| Direct Classification | Macrolide lactams |
| SMILES | CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)C=C(C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)C=CC=CC=C(C)[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OP(C)(C)=O |
| Pathways | |
| PharmGKB | |
| ChEMBL | CHEMBL2103839 |
